Robert W. Baird Cuts MiNK Therapeutics (NASDAQ:INKT) Price Target to $4.00

MiNK Therapeutics (NASDAQ:INKT) had its price objective reduced by Robert W. Baird from $8.00 to $4.00 in a report published on Friday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of MiNK Therapeutics in a research note on Wednesday, October 9th.

MiNK Therapeutics Stock Performance

Shares of MiNK Therapeutics stock opened at $0.75 on Friday. The stock’s fifty day moving average is $0.73 and its 200 day moving average is $0.85. MiNK Therapeutics has a one year low of $0.57 and a one year high of $1.90. The stock has a market cap of $29.81 million, a P/E ratio of -1.93 and a beta of 0.05.

Institutional Investors Weigh In On MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC increased its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned approximately 0.37% of MiNK Therapeutics worth $121,000 at the end of the most recent reporting period. 2.87% of the stock is owned by institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.